期刊文献+

慢性丙型肝炎不同抗病毒药物治疗的临床观察分析 被引量:1

Clinical observation on the antiviral treatment of chronic hepatitis C with different drugs
下载PDF
导出
摘要 目的:评价慢性丙型肝炎(CHC)不同抗病毒药物及方案的疗效与副作用,以优化慢性丙型肝炎治疗策略、提高临床治愈率。方法:动态观察、比较经典治疗组(普通干扰素α/利巴韦林)与聚乙二醇化干扰素α-2 a(PEG-IFNα-2 a)利/巴韦林组的临床疗效及副作用。结果:PEG-IFNα-2 a利/巴韦林组与经典治疗组比较,其快速应答率高,早期的不良反应相对少而轻,对不良反应的总体耐受性好,疗效高并且稳定。结论:PEG-IFNα-2 a联合利巴韦林方案较优,治疗中密切观察处理不良反应、施行个体化治疗方案具有提高总体疗效的意义。 Objective: To evaluate the treatment protocols, efficacy and side effects of anti-HCV drugs, which could be helpful for optimizing the treatment strategy and increasing clinical recovery rate of chronic hepatitis C. Methods: The clinical efficacy and side effects in both routine treatment group (interferon α/ribavirin, B group) and PEG-IFNα-2a/ribavirin treatment group ( A group) were carefully observed, followed up and compared. Results : Higher rate of rapid viral response, less adverse reactions in the early stage, more tolerant and higher total curative rate were observed in PEG-IFNα-2a/ribavirin treatment group than that in B group. Conclusion: The results indicated it' s better using PEG-IFNα-2a/ribavirin to chronic hepatitis C. It might be helpful for increasing the total curative rate. observing, dealing with the adverse reactions ; and using individual anti-viral ther apy strategy.
出处 《中西医结合肝病杂志》 CAS 2008年第4期200-202,共3页 Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases
基金 国家自然科学基金面上项目(No.3406167730771899)
关键词 肝炎 丙型 慢性 干扰素 治疗 hepatitis C chronic interferon therapy
  • 相关文献

参考文献5

二级参考文献57

  • 1丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 2徐道振,谢尧,陆志檬,骆抗先,贾继东,王宇明,赵桂珍,张树林,张大志.聚乙二醇干扰素α-2a与干扰素α-2a治疗慢性丙型肝炎疗效、安全性的评估[J].中华传染病杂志,2004,22(4):221-224. 被引量:37
  • 3李明慧,谢尧,赵辉,欧尉妮,徐道振,陆志檬,骆抗先,贾继东,王宇明,赵桂珍,张树林,张大志.慢性丙型肝炎干扰素治疗后复发患者的干扰素再治疗[J].中华肝脏病杂志,2006,14(1):3-6. 被引量:15
  • 4马烈,赵辉,谢尧,李明慧,徐道振,陆志檬,骆抗先,贾继东,王宇明,赵桂珍,张树林,张大志.干扰素治疗慢性丙型肝炎的持续应答与复发相关因素的研究[J].中华肝脏病杂志,2006,14(8):565-568. 被引量:3
  • 5Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non- responders to interferon monotherapy: a meta- analysis of individual patient data[ J ]. Gut, 2002,51:864-869.
  • 6Papatheodoridis GV, Papadimitropoulos VC, Hsdziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus- reated cirrhosis: a meta- analysis[J] .Aliment Pnarmaool Ther, 2001,15:689- 698.
  • 7Kjaergard LL, Krogsgaard K, Gluud C. Interfern alfa with or without ribavirin for chronic hepatitis C: systematic review of randonmised trials[J].BMJ, 2001,323:1151 - 1155.
  • 8Alberti A, Benvegnu L. Management of hepatitis[J] .J Hepatol, 2003,38(Suppl1): S1014 - S1 18.
  • 9Poynard T, MdHutchison J, Davis GL, et al. Impact of interferon alfa - 2b and ribavirin on progression of liver fibrosiis in patients with chronic hepatitis C[J].Hepatology, 2000,32:1131 - 1137.
  • 10Booth JCL, O' Grady J, Neuberger J. Clinical guidelines on the mangement of hepatitis C[J]. Gut, 2001, 49(Suppl I ): il - i12.

共引文献782

同被引文献15

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部